Teva Pharmaceutical Industries (NYSE:TEVA) Given New $38.00 Price Target at Truist Financial

Teva Pharmaceutical Industries (NYSE:TEVA) had its price target increased by research analysts at Truist Financial from $36.00 to $38.00 in a research note issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Truist Financial’s price objective would suggest a potential upside of 15.51% from the company’s previous close.

Other equities research analysts have also issued reports about the company. Piper Sandler raised their price objective on Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the stock an “overweight” rating in a research report on Monday, December 22nd. Barclays started coverage on shares of Teva Pharmaceutical Industries in a report on Tuesday, December 9th. They set an “overweight” rating and a $35.00 price target for the company. Wall Street Zen lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research note on Sunday, January 18th. Bank of America increased their target price on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $35.67.

Teva Pharmaceutical Industries Trading Down 0.9%

Teva Pharmaceutical Industries stock traded down $0.31 during midday trading on Thursday, reaching $32.90. The stock had a trading volume of 3,028,422 shares, compared to its average volume of 10,375,811. Teva Pharmaceutical Industries has a twelve month low of $12.47 and a twelve month high of $33.43. The company has a debt-to-equity ratio of 2.31, a current ratio of 1.11 and a quick ratio of 0.82. The firm has a market cap of $37.73 billion, a price-to-earnings ratio of 54.91, a PEG ratio of 1.85 and a beta of 0.66. The firm’s fifty day simple moving average is $30.12 and its two-hundred day simple moving average is $22.96.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.13% and a net margin of 4.24%.The company had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. During the same quarter in the prior year, the company earned $0.71 earnings per share. The company’s revenue for the quarter was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Equities analysts anticipate that Teva Pharmaceutical Industries will post 2.5 EPS for the current fiscal year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, Director Roberto Mignone sold 77,400 shares of the stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.24, for a total transaction of $2,340,576.00. Following the transaction, the director directly owned 367,600 shares of the company’s stock, valued at $11,116,224. This represents a 17.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Richard Daniell sold 115,468 shares of the firm’s stock in a transaction dated Tuesday, December 9th. The shares were sold at an average price of $28.68, for a total value of $3,311,622.24. Following the transaction, the vice president owned 48,384 shares in the company, valued at approximately $1,387,653.12. This trade represents a 70.47% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 622,060 shares of company stock valued at $17,076,965. Company insiders own 0.55% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of large investors have recently added to or reduced their stakes in TEVA. Phoenix Financial Ltd. raised its position in shares of Teva Pharmaceutical Industries by 9.4% in the third quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after purchasing an additional 3,533,800 shares during the period. Menora Mivtachim Holdings LTD. boosted its holdings in Teva Pharmaceutical Industries by 1.1% during the third quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company’s stock valued at $786,190,000 after acquiring an additional 427,000 shares during the period. Harel Insurance Investments & Financial Services Ltd. grew its position in shares of Teva Pharmaceutical Industries by 12.9% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock valued at $761,455,000 after purchasing an additional 4,306,363 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 14.8% in the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company’s stock worth $1,167,323,000 after purchasing an additional 4,820,000 shares during the period. Finally, Lingotto Investment Management LLP lifted its position in shares of Teva Pharmaceutical Industries by 1.1% during the 2nd quarter. Lingotto Investment Management LLP now owns 28,156,918 shares of the company’s stock worth $471,910,000 after purchasing an additional 302,975 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

More Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q4 results beat expectations: Teva reported $0.96 EPS vs. $0.65 consensus and revenue of $4.71B vs. $4.36B est., driven by branded-drug sales and margin improvements — a clear near-term earnings beat. Earnings Press Release
• Positive Sentiment: Pipeline / milestone upside: Management disclosed a milestone payment tied to starting a late‑stage study for ulcerative colitis and Crohn’s disease, highlighting potential future revenue streams beyond generics. Reuters: Q4 profit, revenue rise
• Positive Sentiment: Full-year momentum: Teva reported 2025 revenues of ~$17.3B (up ~4% YoY) and management framed the business as executing a “pivot-to-growth” with a strengthening innovative portfolio. This supports a multi-year growth narrative. Globe Newswire: Full-year summary
• Neutral Sentiment: Earnings call and slide deck: Management’s Q&A and the presentation provide detail on product mix, pricing, and pipeline timing — useful for modeling upside but not changing the immediate story. (Call transcript & slides available.) Earnings Call Transcript Earnings Presentation
• Neutral Sentiment: Marketing / awareness initiatives: Teva launched patient-awareness content around Huntington’s disease (celebrity partnership) — positive for reputation and long-term patient engagement but unlikely to move near-term earnings. Yahoo Finance: Will Forte campaign
• Negative Sentiment: Guidance disappointed on revenue: FY‑2026 EPS guidance was set at $2.57–$2.77 (roughly in line with consensus) but revenue guidance of $16.4–$16.8B came in below the ~$17.0B street estimate — a growth/visibility miss that likely pressured the stock. Guidance / Press Release

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.